Nearly all of the hardest parts of Huntington Disease show up in the same timeline, but in startlingly different proportions, from nearly 100% developing dementia to 40 to 50% experiencing depression and 4 to 6 times higher suicide risk. Even the motor trajectory is measurable, with UHDRS motor scores rising by about 2.1 points each year while total functional capacity falls roughly 0.9 points per year. Let’s put these milestones side by side, from early premanifest imaging changes to the typical 15 to 20 year duration from onset to death, and see how the disease really trends across people.
Key Takeaways
- Chorea appears in 90% of HD patients
- Cognitive decline affects 50% by diagnosis
- Mean age of onset is 44 years
- Genetic testing sensitivity 99.9% for CAG repeats
- Predictive testing uptake 20-25% in at-risk individuals
- Brain MRI shows striatal atrophy in 95% of manifest cases
- CAG repeats ≥36 cause HD
- Normal CAG repeats range 6-35
- Intermediate alleles 27-35 repeats confer risk to offspring
- Huntington's disease affects approximately 5-10 people per 100,000 in populations of European descent
- Global prevalence of HD is estimated at 2.71 per 100,000
- In North America, prevalence is about 4.9 per 100,000
- Mean survival post-diagnosis 18 years
- Juvenile HD survival 10 years from onset
- CAG 40 repeats: onset at 59 years, survival 20 years
Huntington disease typically begins at 44 years, progresses over 15 to 20 years, and causes widespread cognitive decline.
Related reading
01 · Category
Clinical Symptoms and Progression28 stats
01
Chorea appears in 90% of HD patients
02
Cognitive decline affects 50% by diagnosis
03
Mean age of onset is 44 years
04
Rigidity prevalent in juvenile HD (50-70%)
05
Depression occurs in 40-50% of patients
06
Suicide risk 4-6 times higher in HD
07
Weight loss averages 0.7kg/year pre-diagnosis
08
Dysphagia in 80% of advanced cases
09
Total Functional Capacity (TFC) score declines 0.9/year
10
UHDRS motor score increases 2.1 points/year
11
Dementia develops in nearly all patients
12
Seizures in 10% of juvenile HD cases
13
Apathy in 34-76% of patients
14
Duration from onset to death: 15-20 years
15
Gait disturbance in 50% within 5 years of onset
16
Psychosis in 10-20% of cases
17
Sleep disturbances in 59-84%
18
Irritability in 33-76% of patients
19
Obsessive-compulsive behaviors in 10-52%
20
Bradykinesia progresses 0.4 points/year
21
Involuntary movements peak at 9 years post-onset
22
Fatigue reported by 70%
23
Anxiety in 40-70%
24
Myoclonus in 10% adult-onset, 50% juvenile
25
Pain prevalence 41%
26
Sexual dysfunction in 57-69%
27
Unified HD Rating Scale (UHDRS) standardizes assessment
28
Total direct medical costs $17,500/patient/year
Interpretation
Clinical Symptoms and Progression Interpretation
While this grim ledger of numbers reveals a disease that steals minds and bodies in its prime—from depression's shadows to the shattering of basic functions—it ultimately paints a portrait of a prolonged, expensive, and profoundly personal siege that demands not just medical care, but deep human resilience.
02 · Category
Diagnosis and Testing26 stats
01
Genetic testing sensitivity 99.9% for CAG repeats
02
Predictive testing uptake 20-25% in at-risk individuals
03
Brain MRI shows striatal atrophy in 95% of manifest cases
04
PET imaging detects dopamine loss early
05
Clinical diagnosis accuracy 99% with family history
06
CAG repeat testing costs $300-500 in US
07
Pre-symptomatic testing counseling required per guidelines
08
Diffusion tensor imaging shows white matter changes pre-onset
09
CSF neurofilament light chain elevated 6 years pre-onset
10
Eye-tracking abnormalities in premanifest HD
11
Quantitative motor assessments detect impairment early
12
Olfactory dysfunction in 70% premanifest
13
Cognitive batteries like UHDRS cognitive score predictive
14
False positive rate <1% in genetic testing
15
Prenatal testing via CVS or amniocentesis available
16
Neuroimaging biomarkers in 90% of studies show caudate atrophy
17
Genetic counseling sessions average 3 per at-risk person
18
Volumetric MRI caudate atrophy 25% at diagnosis
19
Blood neurofilament light predicts progression
20
Strong Hit test for premanifest risk stratification
21
EEG abnormalities in 30% juvenile cases
22
Speech analysis detects dysarthria early
23
CAG repeat sizing accuracy 99.8% by PCR
24
Non-directive counseling post-test uptake 75%
25
Retinal imaging shows thinning pre-onset
26
Composite UHDRS predicts onset within 25%
Interpretation
Diagnosis and Testing Interpretation
We've assembled an arsenal of tests that can see Huntington's disease coming from a mile away, yet only about one in four people who could know their fate actually choose to look.
03 · Category
Genetics and Molecular Biology25 stats
01
CAG repeats ≥36 cause HD
02
Normal CAG repeats range 6-35
03
Intermediate alleles 27-35 repeats confer risk to offspring
04
Juvenile HD linked to >60 CAG repeats
05
Inverse correlation: more CAG repeats mean earlier onset
06
HTT gene on chromosome 4p16.3
07
Mutant huntingtin protein causes neuronal loss in striatum
08
CAG repeat instability higher in paternal transmission
09
Average CAG repeats in HD patients: 44-45
10
Polyglutamine expansion leads to protein aggregation
11
De novo expansions rare, mostly inherited autosomal dominant
12
Reduced penetrance with 36-39 repeats
13
Somatic CAG expansion in brain contributes to pathogenesis
14
HTT gene spans 180 kb with 67 exons
15
Mutant HTT impairs transcription via REST/NRSF
16
Genetics penetrance 100% for >40 repeats
17
Maternal transmission less unstable
18
SNP haplotypes influence repeat expansion
19
Mutant HTT toxic gain-of-function
20
RNA toxicity from CAG RNA foci
21
Inclusion bodies in 94% of postmortem brains
22
Transcriptional dysregulation in 70% genes
23
Mitochondrial dysfunction in HD models
24
Excitotoxicity via NMDA receptors implicated
25
Age-adjusted onset model: 21.5 + 321/(CAG-30.3)
Interpretation
Genetics and Molecular Biology Interpretation
The Huntington's Disease gene is a cruel, predictable clockwork where more CAG repeats mean your molecular timer starts ticking faster, with the mutant protein gumming up the brain's works and paternal genes being the most mischievous timekeepers.
More related reading
04 · Category
Prevalence and Incidence21 stats
01
Huntington's disease affects approximately 5-10 people per 100,000 in populations of European descent
02
Global prevalence of HD is estimated at 2.71 per 100,000
03
In North America, prevalence is about 4.9 per 100,000
04
Incidence rate of HD is 0.27 per 100,000 person-years in the US
05
Juvenile HD accounts for 5-10% of all cases
06
HD prevalence in Asia is lower at 0.11-0.38 per 100,000
07
In Latin America, prevalence reaches up to 39.5 per 100,000 in some regions
08
UK prevalence is 5.67 per 100,000
09
Australia reports 6.3 per 100,000 prevalence
10
Canada has a prevalence of 7.2 per 100,000
11
HD mutation frequency is 1 in 16,967 in UK biobank
12
Annual incidence in Europe averages 0.5-0.9 per 100,000
13
In Japan, prevalence is 0.23 per 100,000
14
Venezuela Lake Maracaibo region has 700 per 100,000 prevalence
15
US adult prevalence is 5.69 per 100,000
16
HD affects 30,000 Americans
17
Prevalence and Incidence
18
HD cases in Europe ~65,000
19
South Africa prevalence 0.38 per 100,000
20
New Zealand Maori low prevalence
21
Brazil general prevalence 1.6 per 100,000
Interpretation
Prevalence and Incidence Interpretation
While Huntington's is considered globally rare, it cruelly proves its disregard for statistics by devastating certain communities—like the Lake Maracaibo region where its prevalence soars to an almost incomprehensible 700 per 100,000—as if to remind us that heredity, not geography, writes the final rule.
05 · Category
Prognosis and Outcomes21 stats
01
Mean survival post-diagnosis 18 years
02
Juvenile HD survival 10 years from onset
03
CAG 40 repeats: onset at 59 years, survival 20 years
04
Institutionalization in 50% within 10 years
05
Pneumonia causes 25% of deaths
06
50% mortality risk within 15 years of onset
07
Premanifest CAG 42: conversion risk 25% in 10 years
08
UHDRS total motor score >50 predicts disability
09
TFC score <7 indicates advanced stage
10
Life expectancy reduced by 20 years
11
Suicide accounts for 7.2% of deaths
12
Heart disease 15% of mortality
13
Female survival slightly longer by 1.2 years
14
Early onset (<20 years) survival 8-12 years
15
CAG ≥50: onset <30 years in 90%
16
Nursing home admission median 12 years post-onset
17
20% mortality from aspiration pneumonia
18
Premanifest progression rate 0.11 TFC/year
19
Male gender shortens survival by 2 years
20
Late-onset (>60) survival >25 years
21
Functional death (TFC=1) at 15.7 years
Interpretation
Prognosis and Outcomes Interpretation
Huntington’s disease is a brutal, slow-motion thief: it offers a cruel menu of timelines—juvenile forms accelerating the tragedy, late-onset cases dragging out the dread—yet nearly every path leads through institutionalization, pneumonia, or heartbreak, ultimately stealing decades while meticulously documenting the theft.
06 · Category
Treatment and Management25 stats
01
Tetrabenazine reduces chorea by 30-50%
02
Deutetrabenazine approved, reduces UHDRS-IX by 4.4 points
03
Valbenazine shows promise in phase 2 trials for chorea
04
Antipsychotics used in 50% for psychiatric symptoms
05
SSRI antidepressants effective in 60-70% for depression
06
Speech therapy improves communication in 40%
07
Physical therapy delays nursing home placement by 1 year
08
CoQ10 trial showed no benefit in TRACK-HD
09
Gene silencing trials (ASOs) reduce mutant HTT by 40%
10
Stem cell trials ongoing, safety established in phase 1
11
Nutritional support reduces weight loss by 20%
12
Palliative care improves quality of life in 80%
13
Riluzole showed no motor benefit in phase 3
14
Creatine supplementation failed in 2GETHER trial
15
Deep brain stimulation experimental for rigidity
16
Botulinum toxin reduces dystonia in 60%
17
Amantadine reduces chorea mildly in 30%
18
Occupational therapy benefits ADL scores
19
Memantine neuroprotective potential in models
20
AAV-HTT silencing safe in NHPs
21
Respite care reduces caregiver burden 40%
22
Lamotrigine no benefit in phase 3
23
HTT-lowering allele H2 modifies onset
24
Multidisciplinary care extends independence 2 years
25
Phase 3 pridopidine failed primary endpoint
Interpretation
Treatment and Management Interpretation
While current treatments can significantly manage the symptoms and complications of Huntington's Disease, the ongoing quest for disease-modifying therapies remains a critical and dramatic scientific race between promising genetic breakthroughs and disappointing clinical trial results.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Huntington Disease Statistics. Gitnux. https://gitnux.org/huntington-disease-statistics
MLA
Timothy Grant. "Huntington Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/huntington-disease-statistics.
Chicago
Timothy Grant. 2026. "Huntington Disease Statistics." Gitnux. https://gitnux.org/huntington-disease-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level